{"id":94053,"date":"2026-05-21T13:54:25","date_gmt":"2026-05-21T08:24:25","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=94053"},"modified":"2026-05-21T13:54:26","modified_gmt":"2026-05-21T08:24:26","slug":"remus-pharmaceuticals-q4-fy26-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/","title":{"rendered":"Remus Pharmaceuticals Q4 FY26 Results: PAT Rs 25 Cr"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p><strong><a href=\"_wp_link_placeholder\" data-wplink-edit=\"true\">Remus Pharmaceuticals<\/a> Q4 FY26<\/strong> results were declared on May 20, 2026. The company reported PAT of Rs 25 crore for the quarter ended March 31, 2026, up 19.0% YoY compared to Rs 21 crore in Q4 FY25. Revenue from operations stood at Rs 453 crore. Results are on a Consolidated basis. Remus Pharmaceuticals is a Pharmaceuticals company listed on Indian stock exchanges.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\">Click Here \u2013 Get Free Investment Predictions<\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#Remus_Pharmaceuticals_Q4_FY26_Financial_Highlights\" title=\"Remus Pharmaceuticals Q4 FY26 Financial Highlights\">Remus Pharmaceuticals Q4 FY26 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#Remus_Pharmaceuticals_Q4_FY26_Performance_Analysis\" title=\"Remus Pharmaceuticals Q4 FY26 Performance Analysis\">Remus Pharmaceuticals Q4 FY26 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#Key_Factors_Driving_Remus_Pharmaceuticals_Q4_FY26_Results\" title=\"Key Factors Driving Remus Pharmaceuticals Q4 FY26 Results\">Key Factors Driving Remus Pharmaceuticals Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#Revenue_and_Operational_Performance\" title=\"Revenue and Operational Performance\">Revenue and Operational Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#Profitability_Trends\" title=\"Profitability Trends\">Profitability Trends<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#India_Macro_Context\" title=\"India Macro Context\">India Macro Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#FY27_Outlook\" title=\"FY27 Outlook\">FY27 Outlook<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#Frequently_Asked_Questions_on_Remus_Pharmaceuticals_Q4_FY26\" title=\"Frequently Asked Questions on Remus Pharmaceuticals Q4 FY26\">Frequently Asked Questions on Remus Pharmaceuticals Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#What_is_Remus_Pharmaceuticals_Q4_FY26_net_profit\" title=\"What is Remus Pharmaceuticals Q4 FY26 net profit?\">What is Remus Pharmaceuticals Q4 FY26 net profit?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#What_is_Remus_Pharmaceuticals_Q4_FY26_revenue\" title=\"What is Remus Pharmaceuticals Q4 FY26 revenue?\">What is Remus Pharmaceuticals Q4 FY26 revenue?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#When_were_Remus_Pharmaceuticals_Q4_FY26_results_declared\" title=\"When were Remus Pharmaceuticals Q4 FY26 results declared?\">When were Remus Pharmaceuticals Q4 FY26 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/remus-pharmaceuticals-q4-fy26-results\/#Is_Remus_Pharmaceuticals_a_good_investment_after_Q4_FY26\" title=\"Is Remus Pharmaceuticals a good investment after Q4 FY26?\">Is Remus Pharmaceuticals a good investment after Q4 FY26?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Remus_Pharmaceuticals_Q4_FY26_Financial_Highlights\"><\/span><strong>Remus Pharmaceuticals Q4 FY26 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26 (Rs Cr)<\/th>\n<th>Q4 FY25 (Rs Cr)<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<tr>\n<td><strong>Revenue<\/strong><\/td>\n<td>453<\/td>\n<td>N\/A<\/td>\n<td>N\/A<\/td>\n<\/tr>\n<tr>\n<td><strong>Net Profit<\/strong><\/td>\n<td>25<\/td>\n<td>21<\/td>\n<td>+19.0%<\/td>\n<\/tr>\n<tr>\n<td><strong>Basis<\/strong><\/td>\n<td colspan=\"3\">Consolidated<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Note: Remus Pharmaceuticals Q4 FY26 results declared May 20, 2026. Data sourced from Screener.in BSE filings. Verify from BSE\/NSE audited financials before investment decisions.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Remus_Pharmaceuticals_Q4_FY26_Performance_Analysis\"><\/span><strong>Remus Pharmaceuticals Q4 FY26 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Remus Pharmaceuticals Q4 FY26<\/strong> results reflect the company&#8217;s financial performance for the January to March 2026 quarter. The quarter demonstrates meaningful profitability with PAT of Rs 25 crore, reflecting strong operational execution. Remus Pharmaceuticals operates in the Pharmaceuticals sector, a segment that benefits from India&#8217;s GDP growth above 6.5% and sustained domestic demand in FY26.<\/p>\n<p>The 19.0% YoY PAT growth in Remus Pharmaceuticals Q4 FY26 reflects the company&#8217;s improving operational efficiency and demand conditions.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\">Screen the best stocks on the Univest Screener.<\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_Driving_Remus_Pharmaceuticals_Q4_FY26_Results\"><\/span><strong>Key Factors Driving Remus Pharmaceuticals Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_and_Operational_Performance\"><\/span><strong>Revenue and Operational Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Remus Pharmaceuticals Q4 FY26 revenue of Rs 453 crore reflects the seasonal and demand dynamics of the Pharmaceuticals sector during the January to March 2026 quarter. India&#8217;s robust macroeconomic backdrop with GDP above 6.5%, government capital expenditure continuity, and resilient domestic consumption supported demand across sectors.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Profitability_Trends\"><\/span><strong>Profitability Trends<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Remus Pharmaceuticals Q4 FY26 PAT of Rs 25 crore up 19.0% YoY. Margin improvement and operating leverage will be the primary levers for sustaining profitability in FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"India_Macro_Context\"><\/span><strong>India Macro Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The January to March 2026 quarter was the fiscal year-end quarter for Indian companies. India&#8217;s Union Budget FY27 allocated Rs 11.21 lakh crore in capital expenditure, and the RBI maintained accommodative liquidity conditions. These macro factors supported demand conditions across manufacturing, services, and consumer sectors during the quarter, benefiting companies operating in the Pharmaceuticals space like Remus Pharmaceuticals.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Outlook\"><\/span><strong>FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Following Remus Pharmaceuticals Q4 FY26 results, investors will monitor management guidance on FY27 revenue trajectory, margin improvement roadmap, and capital allocation priorities. The Pharmaceuticals sector outlook for FY27 is supported by India&#8217;s structural growth drivers including urbanisation, infrastructure investment, and rising consumption.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Remus_Pharmaceuticals_Q4_FY26\"><\/span><strong>Frequently Asked Questions on Remus Pharmaceuticals Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div>\n<div>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Remus_Pharmaceuticals_Q4_FY26_net_profit\"><\/span><strong>What is Remus Pharmaceuticals Q4 FY26 net profit?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<div>\n<p><strong>Ans.<\/strong> <strong>Remus Pharmaceuticals Q4 FY26<\/strong> PAT of Rs 25 crore, up 19.0% YoY from Rs 21 crore in Q4 FY25. Results declared May 20, 2026 on a Consolidated basis. Verify from BSE\/NSE filings.<\/p>\n<\/div>\n<\/div>\n<div>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Remus_Pharmaceuticals_Q4_FY26_revenue\"><\/span><strong>What is Remus Pharmaceuticals Q4 FY26 revenue?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<div>\n<p><strong>Ans.<\/strong> Remus Pharmaceuticals Q4 FY26 revenue from operations was Rs 453 crore as per the quarterly filing for March 2026. Full audited breakdown available on BSE\/NSE.<\/p>\n<\/div>\n<\/div>\n<div>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Remus_Pharmaceuticals_Q4_FY26_results_declared\"><\/span><strong>When were Remus Pharmaceuticals Q4 FY26 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<div>\n<p><strong>Ans.<\/strong> Remus Pharmaceuticals Q4 FY26 results were declared on May 20, 2026, at the board of directors meeting approving audited financial statements for Q4 and full-year FY26.<\/p>\n<\/div>\n<\/div>\n<div>\n<h3><span class=\"ez-toc-section\" id=\"Is_Remus_Pharmaceuticals_a_good_investment_after_Q4_FY26\"><\/span><strong>Is Remus Pharmaceuticals a good investment after Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<div>\n<p><strong>Ans.<\/strong> Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is for educational purposes only. Consult a SEBI-registered financial advisor before investing in Remus Pharmaceuticals.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all figures from BSE\/NSE filings. Consult a SEBI-registered financial advisor.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Remus Pharmaceuticals Q4 FY26 results declared May 20 2026. PAT of Rs 25 crore up 19.0% YoY. Revenue Rs 453 crore. Analysis.<\/p>\n","protected":false},"author":26,"featured_media":94082,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-94053","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1779354557:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["75"],"rank_math_focus_keyword":["Remus Pharmaceuticals Q4"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Remus Pharmaceuticals Q4 FY26 Results: PAT Rs 25 Cr"],"rank_math_description":["Remus Pharmaceuticals Q4 FY26 results declared May 20 2026. PAT of Rs 25 crore up 19.0% YoY. Revenue Rs 453 crore. Analysis."],"_thumbnail_id":["94082"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["12769"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/21135405\/Remus-Pharmaceuticals-Q4-FY26-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/94053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=94053"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/94053\/revisions"}],"predecessor-version":[{"id":94084,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/94053\/revisions\/94084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/94082"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=94053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=94053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=94053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}